MAXON Announces Cinema 4D Release 19

 New Features and Enhancements Streamline Motion Graphics, VFX and VR Content Creation Workflows; First Peeks at Next-Gen Development.



FRIEDRICHSDORF, Germany -Monday, July 31st 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Ahead of the SIGGRAPH 2017 conference, MAXON today announced Cinema 4D Release 19 (R19). This next generation of MAXON’s professional 3D application delivers both great tools and enhancements artists can put to use immediately and provides a peek into the foundations for the future.

Powerful developments have been made to viewport performance, a new Sound Effector and additional features for Voronoi Fracturing have been added to the MoGraph toolset, a new Spherical Camera introduced, the integration of AMD’s ProRender technology and more. Designed to serve individual artists as well as large studio environments, Release 19 offers a fast, easy, stable and streamlined workflow to meet today’s challenges in the content creation markets: especially general design, motion graphics, VFX, VR/AR and all types of visualization.

[NOTE: MAXON will debut Cinema 4D R19 at the upcoming SIGGRAPH 2017 convention July 30 – August 3, in Los Angeles, Booth #701.]

With Cinema 4D Release 19, MAXON also introduces a number of re-engineered foundational technologies, which the company will continue to develop and bring to maturity in future versions. These include core software modernization efforts, a new modeling core, deeply-integrated GPU Rendering for Windows and Mac, and OpenGL capabilities in BodyPaint 3D, MAXON’s professional paint and texturing toolset.

“For more than two decades MAXON has been dedicated to delivering 3D graphics solutions with rock-solid stability, outstanding ease of use, a fast workflow and cross-platform capability,“ says Harald Egel, managing partner at MAXON Computer GmbH. “Cinema 4D Release 19 expands on those core values with outstanding new features and a first look at foundations for the future.”

Complete feature set in Cinema 4D Release R19

Pricing, Availability / Upgrade Path
Cinema 4D Release 19 is scheduled to ship September, 2017.
Pricing and Distribution Information
Recommended System Requirements
Available for both Mac OS X and Windows.

Cinema 4D Release19 Image Links
Cinema 4D Release 19 Information
New in Release 19 Videos
Pressroom

About MAXON

Headquartered in Friedrichsdorf, Germany, MAXON Computer is a developer of professional 3D modeling, painting, animation and rendering solutions. Its award-winning Cinema 4D and BodyPaint 3D software products have been used extensively to help create everything from stunning visual effects in top feature films, TV shows and commercials, cutting-edge game cinematics for AAA games, as well for medical illustration, architectural and industrial design applications. MAXON has offices in Germany, USA, United Kingdom, Canada, France, Japan and Singapore. MAXON products are available directly from the web site and its worldwide distribution channel. MAXON is part of the Nemetschek Group.

Additional information on MAXON can be obtained as follows:

Website: http://www.maxon.net

Facebook: https://www.facebook.com/maxon3d

Twitter: https://twitter.com/maxon3d

YouTube: https://www.youtube.com/user/MaxonC4D

LinkedIn: https://www.linkedin.com/company/791366

Google+: https://plus.google.com/+maxoncinema4d

Instagram: https://www.instagram.com/maxonc4d/

All trademarks contained herein are the property of their respective owners.

Contacts

MAXON
Jessica Wege
+49 6172 5906-643
press_de@maxon.net


Permalink : http://www.me-newswire.net/news/4331/en 

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tablet


BEERSE, Belgium -Friday, July 28th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR).

If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantages of a STR coupled with the high genetic barrier to resistance that darunavir offers.

“Darunavir is one of the most widely used HIV treatments in the European Union due to its ability to control the HIV virus while offering a high barrier to resistance. We will now be able to combine a complete darunavir-based HIV treatment regimen into a once daily tablet. We are extremely excited to be one step closer to getting this therapy to people living with HIV and in doing so hope to reduce the treatment burden faced by many living with the virus,” said Lawrence M. Blatt, Ph.D., Global Therapeutic Area Head, Janssen Infectious Diseases Therapeutics.

“A darunavir-based STR represents a significant evolution in treatment options for HIV patients,” said Jean-Michel Molina, Professor of Infectious Diseases at the University of Paris Diderot. “With around two million people in Europe currently managing their HIV, this is a true advancement in helping patients achieve an undetectable viral load and improving quality of life. Reducing the pill burden allows people greater freedom and flexibility, and through this we may also improve treatment adherence.”

The Positive Opinion is based on a bioequivalence study comparing the once-daily STR with the combined administration of the separate agents darunavir [D] 800 mg, cobicistat [C] 150 mg, and emtricitabine/tenofovir alafenamide [FTC/TAF] 200 mg/10 mg fixed-dose combination. A Phase 3 clinical trial programme investigating the efficacy and safety of the darunavir-based combination is underway. Data on the bioequivalence study, as well as interim data from the Phase 3 Pivotal EMERALD trial in virologically suppressed antiretroviral therapy (ART) experienced patients, who were switched to the STR, will be presented at the upcoming International AIDS Society (IAS) conference in Paris, France. Further EMERALD 48-week data, and 48-week data from the Phase 3 AMBER trial in ART naïve patients, will be released in due course. Please visit www.jnj.com/HIV for further details on the breadth of science being presented by Johnson & Johnson companies and its partners.

The CHMP's Positive Opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorisation for medicines in the European Economic Area. The European Commission’s final decision is anticipated in the coming months.

Janssen have brought medicines to market across a range of patient populations that have helped to transform the efficacy and tolerability of treatment. Treatment regimens that combine D/C (REZOLSTA®, Janssen-Cilag International NV, U.S name PREZCOBIX®) and F/TAF (DESCOVY®, Gilead Sciences International Ltd) are currently approved1,2 for the treatment of HIV. SYMTUZA™ is a significant evolution of this approach, combining both treatments in a single, convenient tablet, and is part of Janssen’s broader commitment to develop effective and innovative therapies which address the issues of adherence and resistance.

###

Notes to editors

On 23 December 2014, Janssen and Gilead Sciences International Ltd amended a licensing agreement for the development and commercialisation of a once-daily STR combination of darunavir and Gilead's TAF, emtricitabine and cobicistat. Under the terms of the agreement, Janssen and its affiliates are responsible for the manufacturing, registration, distribution and commercialisation of this STR worldwide.

About Janssen

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea/ and follow us at @JanssenEMEA.

About PREZISTA® (darunavir)

PREZISTA, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight.

PREZISTA, co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients.

In deciding to initiate treatment with PREZISTA co-administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.

About REZOLSTA® (darunavir/cobicistat)

REZOLSTA is an antiviral medicine used, in combination with other medicines, to treat adults with human immunodeficiency virus type 1 (HIV-1). REZOLSTA contains the active substances darunavir and cobicistat. The medicine is for use only in patients who have not received HIV treatment before or previously treated patients whose disease is not expected to be resistant to darunavir and who are healthy enough and have HIV virus levels below a certain threshold.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive and treatment regimens for HIV. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new indications and therapeutic combinations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the year ended January 1, 2017, including under “Item 1A Risk Factors,” its most recently filed Quarterly Report on Form 10-Q, including in the section captioned “Cautionary Note Regarding Forward-Looking Statements,” and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

References:

1. European Medicines Agency:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002819/human_med_001817.jsp&mid=WC0b01ac058001d124 Last accessed June 2017.

2. European Medicines Agency:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004094/human_med_001978.jsp&mid=WC0b01ac058001d124 Last accessed June 2017.

Contacts

MEDIA CONTACT:
Janssen
Inès Hammer
+ 33 6 88 09 33 35
IHAMMER@its.jnj.com
or
INVESTOR RELATIONS:
Lesley Fishman
Phone: +1 732-524-3922
Joseph J. Wolk
Phone: +1 732-524-1142


Permalink : http://me-newswire.net/news/4320/en

Schlumberger Announces Second-Quarter 2017 Results

PARIS-Wednesday, July 26th 2017 [ ME NewsWire ]

• Revenue of $7.5 billion increased 8% sequentially
• Pretax operating income of $950 million increased 25% sequentially
• GAAP loss per share, including charges of $0.40 per share, was $0.05
• EPS, excluding charges, was $0.35
• Quarterly cash dividend of $0.50 per share was approved

(BUSINESS WIRE)-- Schlumberger Limited (NYSE:SLB) today reported results for the second quarter of 2017.

				(Stated in millions, except per share amounts)
				Three Months Ended												Change
				Jun. 30, 2017				Mar. 31, 2017				Jun. 30, 2016				Sequential				Year-on-year
Revenue				$7,462				$6,894				$7,164				8	%			4	%
Pretax operating income				$950				$757				$747				25	%			27	%
Pretax operating margin				12.7	%			11.0	%			10.4	%			175 bps				231 bps
Net income (loss) (GAAP basis)				$(74	)			$279				$(2,160	)			n/m				n/m
Net income, excluding charges & credits*				$488				$347				$316				41	%			54	%
Diluted EPS (loss per share) (GAAP basis)				$(0.05	)			$0.20				$(1.56	)			n/m				n/m
Diluted EPS, excluding charges & credits*				$0.35				$0.25				$0.23				40	%			52	%
*These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details.
n/m = not meaningful

Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our second-quarter revenue increased 8% sequentially while pretax operating income rose by 25%, resulting in earnings per share growth of 40%. Beyond seasonal effects, revenue grew in all of our Groups and Areas.
“North America revenue increased 18% following our rapid deployment of idle hydraulic fracturing capacity as land activity further accelerated during the second quarter, partially offset by further weakness offshore in the US Gulf of Mexico. In US land, revenue grew 42% sequentially, a rate almost double that of the 23% increase in land rig count, driven primarily by hydraulic fracturing revenue that grew 68% as completions activity intensified and pricing continued to improve. Directional drilling revenue in US land was also higher as longer laterals requiring rotary steerable systems and advanced drillbit technologies continued to drive drilling intensity. Despite the significant costs associated with reactivating equipment, all of our US land product lines were profitable in the second quarter, driven by higher pricing, market share gains, improved operational efficiency, timely resource additions, and proactive supply chain management.
“In the international markets, revenue increased 4% sequentially, led by Europe/CIS/Africa as activity recovered from the winter slowdown in Russia and the North Sea. Latin America revenue increased due to higher reservoir characterization and drilling activities in the Mexico & Central America GeoMarket, as well as from increased unconventional land activity in Argentina. The Middle East & Asia Area benefited from a seasonal rebound in China, increased activities in Southeast Asia, and higher Integrated Drilling Services (IDS) activity in Iraq.
“Among the business segments, growth in the second quarter was led by the Production and Drilling Groups, where revenue increased sequentially by 14% and 6%, respectively, as hydraulic fracturing and directional drilling activity in US land accelerated. Reservoir Characterization Group revenue increased 9% due to higher international activities beyond the seasonal rebounds in the Russia & CIS and North Sea regions. Cameron Group revenue also increased 3% sequentially driven by higher project volume and product sales for Surface Systems and Valves & Measurement in North America.
“While the activity outlook in North America for the second half of the year remains robust, we are now also seeing more positive signs in the international markets with increases in activity and new project plans starting to emerge in several GeoMarkets. The strengthening in the international markets has so far been concentrated around land activity in Western Siberia and in the OPEC Gulf countries but we are now also seeing an increasing number of new offshore projects being prepared for tendering and final investment decision (FID) in many of the world’s shallow water basins.
“In this market, we continue to focus on serving our customers and driving our business forward, building on our successful efforts over the past three years of broadening our technology portfolio and increasing our addressable market, further streamlining our execution machine, and pursuing more collaborative and commercially aligned ways of working with new and existing customers.
“As part of this focus, we announced a new agreement yesterday to acquire a majority equity interest in the Eurasia Drilling Company (EDC). This extends the successful long-term relationship that we have enjoyed with EDC through the strategic alliance that we signed in 2011. Closing of the transaction is subject to approval by the Federal Antimonopoly Service of Russia.
“We also remain on track to close the OneStim^SM joint venture transaction in the second half of this year, which will allow us to further capitalize on the recovery in North America land unconventional activity. At the same time, our increasing investments in Schlumberger Production Management through the new projects with OneLNG, YPF, and NNPC and FIRST E&P are not only providing additional short-term opportunities for our various product lines, but also a long-term activity baseline with superior full-cycle financial returns for the company as a whole.
“Based on these, we continue to be optimistic about the future of Schlumberger, as we maintain an attentive watch and flexible approach to the shape and pace of the emerging oil market recovery.”



 View the full article at: http://me-newswire.net/news/4315/en

Foxconn and Rockwell Automation Announce Partnership to Implement Industry-Leading IIoT Solutions at Foxconn’s Consumer Electronics Assembly Operations

MILWAUKEE -Sunday, July 30th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Hon Hai Precision Industry Co., Ltd., also known as Foxconn, and Rockwell Automation announced today that they are collaborating to implement Connected Enterprise and Industrial Internet of Things (IIoT) concepts for smart manufacturing in Foxconn's new U.S. facilities.

The companies will also collaborate to develop and apply Smart Manufacturing solutions at Foxconn's global electronics assembly operations and within the related industry eco-system. Technologies and extensive domain expertise of both companies will be combined to deliver a state of the art manufacturing system with unparalleled levels of operational efficiency.

Terry Guo, Foxconn Chairman and CEO, said, "I am very excited about the opportunity for Foxconn and Rockwell Automation to work together. Foxconn is the global leader in electronics design manufacturing, and Rockwell Automation is the world’s largest company dedicated to industrial automation and information. I am confident that together we will increase operational efficiencies in electronics manufacturing to new levels, achieving the vision of Smart Manufacturing and Made in China 2025."

The companies will also work together on workforce development and training. Specifically, as Foxconn increases its employee base in the United States, it has committed to participate in the previously-announced program developed by Rockwell Automation and ManpowerGroup to upskill military veterans and create a pool of certified talent for in-demand advanced manufacturing roles across the United States.

Blake Moret, Rockwell Automation President and CEO added, “We are excited about the opportunity to work with a global technology and manufacturing leader to deliver advanced IIoT solutions to the electronics manufacturing industry. Our work with Foxconn will further demonstrate the power and broad applicability of The Connected Enterprise. We are also pleased that Foxconn shares our commitment to expanding and upskilling the U.S. workforce to ensure there is the necessary talent for advanced manufacturing roles.”

About Foxconn

Established in 1974, Foxconn Technology Group (“Foxconn”), under the leadership of Founder and CEO Terry Gou, offers the most competitive production manufacturing technology in the world. A recognized global industry leader, Foxconn created the 3C OEM service business model, eCMMS, incorporating vertical integration of mechanical, optical, and electronic components. Foxconn offers many of the world’s leading companies a one-stop integrated manufacturing solution. Foxconn has in recent years expanded into technology services, providing customers the most comprehensive solutions for their technology and manufacturing needs. In addition to maximizing value creation for customers, Foxconn is also dedicated to enhancing the concept of environmental protection in the manufacturing process. In addition to being a trusted partner for its customers, Foxconn is working to be a best-practices model for global enterprises.

About Rockwell Automation

Rockwell Automation Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and information, makes its customers more productive and the world more sustainable. Headquartered in Milwaukee, Wis., Rockwell Automation employs approximately 22,000 people serving customers in more than 80 countries.

This news release contains statements that are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Words such as “believe”, “plan”, “expect”, “anticipate”, “will”, “intend” and other similar expressions may identify forward-looking statements. Our plans may change and the relationship may differ materially from what is described as a result of certain risks and uncertainties, many of which are beyond our control, including but not limited to challenges and uncertainties inherent in finalizing and implementing arrangements of the type that this release describes; macroeconomic factors; and other risks and uncertainties, including but not limited to those detailed from time to time in our SEC filings. These forward-looking statements reflect our beliefs as of the date of this release. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Bruce Quinn
Vice President Public Affairs
Rockwell Automation
202.215.9782 – mobile

Permalink : http://me-newswire.net/news/4322/en

DMS’ new Video Product selected to safeguard Unilever’s stringent viewability and brand safety guidelines

Choueiri Group’s digital media arm secures regional-first exclusive launch partner agreement with PHD UAE for Unilever

Dubai ,United Arab Emirates-Monday, July 31st 2017 [ ME NewsWire ]
Digital Media Services (DMS), which serves as the official digital media arm of Choueiri Group recently announced that it has entered into an exclusive launch partner agreement with PHD UAE (The digital media planning and buying agency for Unilever North Africa & Middle East) for their new DMS Video Product.
The pioneering partnership is aimed at safeguarding Unilever’s investments as an advertiser and secures an online video inventory that adheres to the marketer’s stringent viewability guidelines, at a time when brand safety is becoming a growing concern.
Under the scope of the agreement, Unilever will receive privileged access to DMS’ vast portfolio of premium video properties. These include the region’s foremost video-on-demand service Shahid, along with Daily Motion and OLN.
Aside from extending its portfolio of complementary video platforms, DMS has also recently collaborated with TEADS to further diversify and enhance the scale of its video inventory. This consolidated approach has led to one unified DMS Video proposition, which uniquely leverages the power of DMS’ different video platforms and formats, to focus on planning for reach and planning for synergy. With the new Video Product, advertisers can reach 75% of the MENA population in a 100% brand safe environment, leverage DMS’ data and targeting capabilities and guarantee viewability way above the global average – all while achieving higher impact on brand metrics at a competitive CPcV (Cost Per Completed View).

DMS is also making significant efforts to provide strong measurement standards for marketers and advertisers to evaluate and optimize their digital investments. This includes working with Moat as well as their ongoing commitment to top-quality, locally produced content.
The move provides better leverage and scale than was previously achievable, as Unilever will now enjoy exclusive strategic planning and trading benefits, while ensuring its video ads are viewed within a quality and safe environment.
“Digital video advertising is a very significant part of our media investment so a partnership like this, delivering both qualitatively and quantitatively, is fantastic news,” commented Asad Ur Rehman, Director of Media for Unilever North Africa & Middle East. “We’re really excited about the higher level of control this new approach provides us to build our brands safely and effectively in a desirable environment.”
Luca Allam, Managing Director of PHD UAE also commented on the pioneering agreement by stating, “Challenging the status quo is something we’ve been doing from day one so this opportunity to take digital video planning and buying to a higher level was a natural step for us. Every innovation, every initiative, every media partnership is designed to meet the needs of our clients, individually or collectively. This mutually beneficial deal for DMS and Unilever will elevate their respective performance and that’s a major step forward for digital marketing in the region.”
Elaborating further on DMS Video, Chief Operating Officer Michel Malkoun reiterated the benefits by saying “With the region's population consuming digital video at record rates, video viewership among young people in MENA is already amongst the highest in the world. DMS’ Video product promises “One Audience, One Platform”. Alongside the most engaging premium video content, DMS Video embraces brand safety and standardization in measurability at its core. This will enable our valued advertising partners such as Unilever to not only realize better outcomes, but it will also assist them to gauge and optimize their digital investments.
About Digital Media Services (DMS):
Digital Media Services (DMS) was incorporated in 2010 as the official digital media arm of Choueiri Group. Today, the Company extends a premium portfolio of online / mobile offerings, which reach 120 million Unique Users, generate 2 Billion Page Views and serve over 3.2 billion ads per month. Aligned with Choueiri Group’s commitment to and focus on digital, DMS received a brand makeover in April 2017, which expresses its unique strength as the true voice of independent publishers. DMS is headquartered in Dubai, with presence in key regional markets.

Contacts
DMS / Choueiri Group:

Assad Jamil, +971-4-454-54-54

ajamil.mr@choueirigroup.com 

Permalink : http://me-newswire.net/news/4329/en

I Squared Capital to Acquire Hutchison Global Communications, a Leading Fixed-Line Service Provider in Hong Kong

HONG KONG -Sunday, July 30th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- I Squared Capital, an independent global infrastructure investment manager, has signed an agreement, through its ISQ Global Infrastructure Fund II, to acquire a 100 percent interest in Hutchison Global Communications Investment Holding Limited (HGC) from Hutchison Telecommunications Hong Kong Holdings Limited (HTHKH) for approximately HKD14.5 billion. The transaction is expected to close by October 2017.

HGC is a leading fixed-line service provider to fixed and mobile carriers, OTT service providers, corporate and business, residential and data centers in Hong Kong and around the world. Its over 1.4-million-kilometer fiber network connects to over 14,200 buildings and it is also one of Hong Kong’s largest-scale Wi-Fi service providers with over 25,000 Wi-Fi hot spots. The company’s extensive international network has four highly prized land routes into mainland China. The company extends its global reach into different continents through multiple submarine and terrestrial cable systems. Much of HGC’s revenue is under long-term contracts to a diverse base of customers, including the major mobile providers in the region.

Commenting on the acquisition, Gautam Bhandari, Partner at I Squared Capital, said: “As a premier global hub for commerce and telecommunications, Hong Kong benefits from innovative products and world class services. With I Squared Capital’s investment, HGC will continue to provide the same quality of service that mobile telecommunication providers, corporate and residential customers have come to expect. Fresh capital will also enable the company to develop new solutions to meet the ever-increasing demand for high-speed information infrastructure throughout the region and beyond.”

About HGC Group: The HGC Group is a leading fixed-line operator, IT service provider, carrier’s carrier and one of Hong Kong’s largest-scale Wi-Fi service providers. The HGC Group empowers local and overseas customers with one-stop international, carrier, corporate, data centre and residential broadband services. The HGC Group owns and runs an extensive optical-fibre network, coupled with four cross-border routes integrated with three of mainland China’s tier-one telecoms operators, plus a world-class international network. The HGC Group is committed to developing cloud computing services and offering high-speed Wi-Fi service under the “HGC On Air“ brand. HGC is a subsidiary of Hutchison Telecommunications Hong Kong Holdings Limited (stock code: 215), a group member of CK Hutchison Holdings (stock code: 1).

About I Squared Capital: I Squared Capital is an independent global infrastructure investment manager focusing on energy, utilities, and transport in the Americas, Europe, and select high growth economies. The Firm has offices in New York, Houston, London, New Delhi, Hong Kong and Singapore.



Contacts

I Squared Capital
Andreas Moon, +1-212-339-5339
Managing Director and Head of Investor Relations
andreas.moon@isquaredcapital.com



Permalink : http://me-newswire.net/news/4328/en

Physicist sees quantum computers ushering in major progress in all fields of science within 20 years

 Winners of King Faisal International Prize for Science 2017 offer insights into major developments in quantum physics


Riyadh,Saudi Arabia.-Sunday, July 30th 2017 [ ME NewsWire ]

The world is expected to enter the era of quantum computing in the next 20 years as new breakthroughs in quantum physics offer the possibility of creating computers with unbelievable speed and power that can surpass the capabilities of today’s traditional computers, stated Professor Daniel Loss, co-winner of the King Faisal International Prize for Science 2017.

Professor Loss was honoured with the prestigious award this year for his pioneering work on the study of spin dynamics and spin coherence of very small semiconductor particles called quantum dots, that promises to open up significant new opportunities in practical applications based on quantum computing.

Loss, who is the Professor of the Department of Physics at the University of Basel, shared the prestigious prize this year with Professor Laurens Molenkamp of the University of Wurzburg.

Delivering a lecture at the King Abdulaziz City for Science and Technology in Riyadh, Professor Loss stated: “There is a growing list of things that can be done better and faster using quantum computers in all areas of science, mainly because of the incredible search and calculation abilities of such computers.”

Professor Loss pointed out that controlling the spin state of electrons in a coherent position for long is still a challenge. This is the reason why the quantum computer is getting delayed, he said.

Recalling that Peter Williston Shor from the US won the King Faisal International Prize for Science in 2002 for his work on quantum computation and quantum algorithm, Daniel said: “I am very pleased to have received this prize which was earlier won by Peter Shor for formulating the Shor Algorithm, one of the most important contributions in the field of quantum computing today.”

Speaking at the lecture, Professor Laurens Molenkamp shed light on topological superconductivity, which is considered a crucial area of research with practical application prospects in a number of areas, including quantum computing.

His findings have much relevance in the development of topological insulators, which are insulators that lets electrons move along the surface, but not through the inside.

The King Faisal International Prize has been awarding outstanding contributions in the field of science alternating between the subcategories of physics, chemistry, biology and mathematics. The renowned award had earlier recognized two scientists for their research on semiconductors. Sir Richard Friend from the UK won the award in 2009 for his study of semiconductor physics of conjugated polymers, while Federico Capasso from the US received the award in 2005 for his work on semiconductor nanostructures and invention of quantum cascade laser.

To know more about King Faisal International Prize, visit our website:  www.kfip.org .

Contacts

Hussain Abu Hajer, +96656-868-5008

Email: Hussain@hadathgroup.com

Or

Rima Abuobaid

UAE – M: +97150 9155921, KSA – M: +96655 6890730

rima@hadathgroup.com;
























Permalink : http://www.me-newswire.net/news/4107/en 

NEW YORK -Sunday, July 30th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Moody’s Corporation (NYSE:MCO) announced today that it has received clearance under the EU Merger Regulation from the European Commission to acquire Bureau van Dijk, a global provider of business intelligence and company information. Moody’s announced that it had agreed to acquire Bureau van Dijk on May 15, 2017.

In accordance with the terms of the transaction, Moody’s expects the acquisition to be completed in August 2017.

Bureau van Dijk aggregates, standardizes and distributes one of the world’s most extensive private company datasets, with coverage exceeding 220 million companies. It has partnerships with more than 160 independent information providers, creating a platform that connects customers with data that addresses a wide range of business challenges. Bureau van Dijk’s solutions support the credit analysis, investment research, tax risk, transfer pricing, compliance and third-party due diligence needs of financial institutions, corporations, professional services firms and governmental authorities worldwide.

Moody’s will consolidate Bureau van Dijk’s financial results beginning on the closing date and expects to provide updated full year 2017 guidance that includes Bureau van Dijk as part of its third quarter 2017 earnings release.

ABOUT MOODY'S CORPORATION

Moody's is an essential component of the global capital markets, providing credit ratings, research, tools and analysis that contribute to transparent and integrated financial markets. Moody’s Corporation (NYSE:MCO) is the parent company of Moody's Investors Service, which provides credit ratings and research covering debt instruments and securities, and Moody's Analytics, which offers leading-edge software, advisory services and research for credit and economic analysis and financial risk management. The corporation, which reported revenue of $3.6 billion in 2016, employs approximately 10,600 people worldwide and maintains a presence in 36 countries. Further information is available at www.moodys.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this release are forward-looking statements and are based on future expectations, plans and prospects for Moody’s business and operations that involve a number of risks and uncertainties. The forward-looking statements in this release are made as of the date hereof, and Moody’s disclaims any duty to supplement, update or revise such statements on a going-forward basis, whether as a result of subsequent developments, changed expectations or otherwise. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Moody’s is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, world-wide credit market disruptions or an economic slowdown, which could affect the volume of debt and other securities issued in domestic and/or global capital markets; other matters that could affect the volume of debt and other securities issued in domestic and/or global capital markets, including regulation, credit quality concerns, changes in interest rates and other volatility in the financial markets such as that due to the U.K.’s referendum vote whereby the U.K. citizens voted to withdraw from the EU; the level of merger and acquisition activity in the U.S. and abroad; the uncertain effectiveness and possible collateral consequences of U.S. and foreign government actions affecting world-wide credit markets, international trade and economic policy; concerns in the marketplace affecting our credibility or otherwise affecting market perceptions of the integrity or utility of independent credit agency ratings; the introduction of competing products or technologies by other companies; pricing pressure from competitors and/or customers; the level of success of new product development and global expansion; the impact of regulation as an NRSRO, the potential for new U.S., state and local legislation and regulations, including provisions in the Financial Reform Act and regulations resulting from that Act; the potential for increased competition and regulation in the EU and other foreign jurisdictions; exposure to litigation related to our rating opinions, as well as any other litigation, government and regulatory proceedings, investigations and inquires to which the Company may be subject from time to time; provisions in the Financial Reform Act legislation modifying the pleading standards, and EU regulations modifying the liability standards, applicable to credit rating agencies in a manner adverse to credit rating agencies; provisions of EU regulations imposing additional procedural and substantive requirements on the pricing of services; the possible loss of key employees; failures or malfunctions of our operations and infrastructure; any vulnerabilities to cyber threats or other cybersecurity concerns; the outcome of any review by controlling tax authorities of the Company’s global tax planning initiatives; exposure to potential criminal sanctions or civil remedies if the Company fails to comply with foreign and U.S. laws and regulations that are applicable in the jurisdictions in which the Company operates, including sanctions laws, anti-corruption laws, and local laws prohibiting corrupt payments to government officials; the impact of mergers, acquisitions or other business combinations and the ability of the Company to successfully integrate acquired businesses; currency and foreign exchange volatility; the level of future cash flows; the levels of capital investments; and a decline in the demand for credit risk management tools by financial institutions. Other factors, risks and uncertainties relating to our pending acquisition of Bureau van Dijk could cause our actual results to differ, perhaps materially, from those indicated by these forward-looking statements, including the ability of the parties to successfully complete the proposed acquisition on anticipated terms and timing, or at all; the possibility that the conditions to closing may not be satisfied and the transaction will not be consummated; risks relating to the integration of Bureau van Dijk’s operations, products and employees into Moody’s and the possibility that anticipated synergies and other benefits of the proposed acquisition will not be realized in the amounts anticipated or will not be realized within the expected timeframe; risks that the proposed acquisition could have an adverse effect on the business of Bureau van Dijk or its prospects, including, without limitation, on relationships with vendors, suppliers or customers; claims made, from time to time, by vendors, suppliers or customers; changes in the European or global marketplaces that have an adverse effect on the business of Bureau van Dijk; and other factors, risks and uncertainties relating to the transaction as set forth under the caption “‘Safe Harbor’ Statement under the Private Securities Litigation Reform Act of 1995 ” in Moody’s report on Form 8-K filed on May 15, 2017, which are incorporated by reference herein. These factors, risks and uncertainties as well as other risks and uncertainties that could cause Moody’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements are described in greater detail under “Risk Factors” in Part I, Item 1A of the Company’s annual report on Form 10-K for the year ended December 31, 2016, and in other filings made by the Company from time to time with the SEC or in materials incorporated herein or therein. Stockholders and investors are cautioned that the occurrence of any of these factors, risks and uncertainties may cause the Company’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements, which could have a material and adverse effect on the Company’s business, results of operations and financial condition. New factors may emerge from time to time, and it is not possible for the Company to predict new factors, nor can the Company assess the potential effect of any new factors on it.

Contacts

Salli Schwartz
Global Head of Investor Relations and Communications
212.553.4862
sallilyn.schwartz@moodys.com
or
Michael Adler
Senior Vice President, Corporate Communications
212.553.4667
michael.adler@moodys.com

Permalink : http://www.me-newswire.net/news/4326/en

Sagemcom Announces the Acquisition of Meter Italia S.p.A.

RUEIL-MALMAISON, France -Sunday, July 30th 2017 [ ME NewsWire ]
(BUSINESS WIRE)-- SAGEMCOM STRENGTHENS ITS POSITIONS ON THE MULTI-ENERGY MARKET, BY ACQUIRING METER ITALIA S.P.A, LEADER IN GAS METERING IN ITALY.
As of July 27, 2017, Sagemcom becomes a 100% shareholder of Meter Italia S.p.A through its subsidiary Sagemcom Energy & Telecom SAS. Meter Italia joins the Sagemcom group and becomes Sagemcom Italia S.p.A.
This acquisition represents an opportunity for the Sagemcom Group to access and actively participate in the growth of the gas metering market. Meter Italia has a complete portfolio of traditional and smart residential gas meter, as well as a range of industrial gas meters.
Combining the competencies of Meter Italia and Sagemcom will also allow Sagemcom to address new technology breakthroughs in the world of multi-energy metering, in order to meet the expectations of the market and its customers.
For Patrick Sevian, CEO of Sagemcom, « This acquisition is at the heart of our growth strategy, especially because the smart multi-energy metering market is a promising future for our Group. This strengthens our position as a leader of the multi-energy metering market, specifically in EMEA thanks to Meter Italia's positions and our presence on the Italian market. We are pleased to see Meter Italia join Sagemcom ».
"The integration of an actor like Meter Italia is a real opportunity to immediately become a major player in gas, thanks to the combination of Meter Italia's know-how and reputation in the manufacture of gas meters, together with Sagemcom's expertise in energy management solutions, communication infrastructures and IoT" adds Eric Rieul, VP of Sagemcom Energy & Telecom.
“Joining the Sagemcom Group is a tremendous opportunity for Meter Italia. We will be able to get support from a structure and teams that will allow us to develop our business internationally” concludes Boris Ferraresi, CEO of Meter Italia.
About Sagemcom
A French high-tech group of international dimensions, Sagemcom operates on the broadband (digital home, set-top boxes, Internet routers, telephony and multimedia terminals), smart city (smart meter, smart grid, smart infra, smart sites and smart services), and Internet of Things markets.
With revenue of around 1.6 billion euros, Sagemcom employs 4000 people on five continents and ships every year more than 25 million terminals. Sagemcom aims to remain a world leader in communicating terminals with high added value.
www.sagemcom.com // www.facebook.com/SagemcomOfficial // https://twitter.com/Sagemcom
Contacts
SAGEMCOM
Media
Sylvaine COULEUR, 00336-99-37-63-48
presse@sagemcom.com

Permalink : http://me-newswire.net/news/4325/en

IBC Announces Speaker Line Up for Audiences and Advertising Conference Stream

 - Sessions focussed on realities of changing consumer landscape and reaching, engaging and monetising viewers -



LONDON -Saturday, July 29th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- IBC announces today the programme for the Audiences and Advertising Conference Stream, which will be held on Saturday 16th September. With broadcasters and media companies operating in an increasingly fragmented multi-platform TV market, the stream will explore where and how audiences are moving and the latest innovations in viewing and advertising technologies.

This exciting stream at IBC features high-profile speakers including:

Jeff Binder, CEO - Layer3 TV and Tom Pickett, CEO – Ellation who will be talking about the disruption of the US broadcasting industry.

Orpheus Warr, CTO – C4 and Adrian Drury, Director of Technology Strategy & Insight – Liberty Global who will be sharing their views on the most exciting new technologies and devices transforming the TV market.

Christopher Mead, Senior Director of Partnerships EMEA – Twitch who will be joining a panel to discuss the new online video ecosystem – who’s watching, what makes it one of the fastest growing parts of the TV market, and what can broadcasters learn from the new video players.

Ashwin Navin, CEO – Samba TV who will be talking about latest and most exciting developments in TV advertising - addressable, cross platform, data driven, dynamic and real-time.

Vaughn McKenzie-Landell, founder – Jaak and a panel of innovative new businesses will be speaking about the merits and uses of block chain across the broadcasting and entertainment industries.

Jon Watts, Executive Producer and Managing Partner at MTM said; “The Audiences and Advertising stream this year is the best yet. We’ve got a diverse range of speakers from some of the world’s largest media businesses, leading technology providers and most exciting start-ups – and will be exploring some of the most exciting and important developments in the broadcasting world. We’ve got demos of next-generation TV features and advertising, visions of the future, showcases and debates.”

## ENDS ##

About IBC

IBC is the world’s leading media, entertainment and technology show. It attracts 55,000+ attendees from more than 170 countries and combines a highly respected and peer-reviewed conference with an exhibition that showcases more than 1,700 leading suppliers of state of the art electronic media and entertainment technology.

IBC2017 Dates

Conference: 14 – 18 September 2017

Exhibition: 15 – 19 September 2017

For more information about IBC2017 visit: https://show.ibc.org/

Contacts

IBC
Louise Wells, Bubble Communications
E: louisew@bubbleagency.com
T: +44 7718 985 252


Permalink : http://me-newswire.net/news/4324/en

Takeda Reports 1st Quarter FY2017 Results

 Strong start to FY2017 with double-digit EPS growth; confirms confidence in full-year outlook

OSAKA, Japan -Saturday, July 29th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502):

Underlying Revenue growth of 6.6% led by Takeda's Growth Drivers

    Underlying Revenue grew +6.6% with growth across all regions (U.S. +13.5%, Japan +1.6%, Europe & Canada +4.6%, Emerging Markets +6.0%). Takeda's Growth Drivers (GI, Oncology, CNS and Emerging Markets) maintained their strong momentum to deliver growth of +14.7%.
        GI (Gastroenterology) +23.2%, led by continued success of ENTYVIO® and TAKECAB®
        Oncology +12.2%, driven by NINLARO®, ADCETRIS®, ICLUSIG® and ALUNBRIGTM
        CNS +29.8%, spearheaded by TRINTELLIX® in the U.S.
        Emerging Markets +6.0%, with double-digit growth in the key markets of Russia and Brazil
    Reported revenue grew +3.3%, with the positive contribution from Takeda's Growth Drivers offsetting the impact of unfavorable currencies (-0.4pp) and divestitures (-2.9pp).

Double-digit EPS growth driven by Revenue growth and significant margin gains

    Underlying Core Earnings grew +29.4%, with a margin increase of 350bps driven by an improvement in Gross Margin and continued OPEX discipline.
    Reported operating profit was up +27.5%, driven by strong underlying growth. Takeda realized a one-time gain in Q1 FY2017 of 106.3 billion yen from the sale of shares of Wako Pure Chemical Industries, Ltd. This was similar in size to the Teva JV transaction gain of 102.9 billion yen in Q1 FY2016, and therefore the impact on our year-on-year growth rate was minimal.
    Underlying Core EPS was up +35.7%, reflecting strong Core Earnings growth and a phasing benefit from tax rate. Reported EPS increased +45.8% to 186 yen per share.

Significant progress on Cash Flow and reduced net leverage

    Operating Free Cash Flow increased +50.3% to 55.5 billion yen.
    Sale of non-core assets generated an additional 128 billion yen of cash.
    Net Debt / EBITDA drops from 2.7x at end of FY2016 to 2.1x

James Kehoe, Chief Financial Officer of Takeda, commented:

"Takeda delivered a strong start to the year on both revenue and profitability, driven by the continued strength of our Growth Drivers and good progress on our cost management initiatives. We are executing well against our key priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability, and the first quarter results confirm our confidence in the full-year outlook for double-digit EPS growth."


Reported Results for Q1 (April - June) FY2017


(billion yen)           FY2016 Q1           FY2017 Q1           Growth
                  Reported           Underlying2
Revenue           434.0           448.2           +3.3%           +6.6%
Core Earnings1           77.1           106.3           +37.9%           +29.4%
Operating Profit           152.9           195.0           +27.5%           -
Net Profit3           99.5           144.8           +45.5%           +35.7%
EPS           127 yen           186 yen           +45.8%           -
Core EPS           71 yen           103 yen           +44.5%           +35.7%
1           Core Earnings is calculated by taking reported Gross Profit and deducting SG&A expenses and R&D expenses. In addition, certain other items that are non-core in nature and significant in value may also be adjusted.
2           Underlying growth compares two periods of financial results on a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures from both periods.
3           Attributable to the owners of the company.


Takeda maintains its Management Guidance and Reported Forecast for FY2017, projecting double-digit EPS growth.


FY2017 Management Guidance
                                         
                                                      Guidance (growth %)
                                          Underlying Revenue           Low single digit
                                          Underlying Core Earnings           Mid-to-high teen
                                          Underlying Core EPS           Low-to-mid teen
                                          Annual dividend per share           180 yen


FY2017 Reported Forecast
                                   
                                    (billion yen)           FY2016 Results           FY2017 Forecast           % change
                                    Revenue           1,732.1           1,680.0           -3.0%
                                    Core Earnings           245.1           257.5           +5.0%
                                    Operating Profit           155.9           180.0           +15.5%
                                    Net Profit           114.9           138.0           +20.1%
                                    EPS           147 yen           177 yen           +20.1%
                                    Exchange Rate
(annual average)           1 US$= 109 yen

1 euro= 120 yen
          1 US$= 110 yen

1 euro= 120 yen
         


For more details on Takeda’s FY2017 first quarter results and other financial information please visit https://www.takeda.com/investors/reports/

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in Emerging Markets, are currently fueling the growth of Takeda. Around 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.

Contacts

Investor Relations
Takeda Pharmaceutical Company Limited
+81-(0)3-3278-2306
takeda.ir.contact@takeda.com
Media Relations
Takeda Pharmaceutical Company Limited
Tsuyoshi Tada, +81 (0)3-3278-2417
tsuyoshi.tada@takeda.com

Permalink : http://www.me-newswire.net/news/4323/en

Shiseido Supports "teamLab: A Forest Where Gods Live Art Exhibition presented by Shiseido"

TOKYO -Saturday, July 29th 2017 [ ME NewsWire ]
(BUSINESS WIRE)-- Shiseido Company, Limited (hereinafter “Shiseido”)(TOKYO:4911) supports “teamLab: A Forest Where Gods Live Art Exhibition presented by Shiseido”, hosted by Mifuneyama Rakuen and teamLab Inc. (hereinafter “teamLab”). The exhibition was first held by teamLab in 2015 based on the concept “Nature Becomes Art”; this year marks the third edition, with Shiseido supporting the event for the first time.
The venue, Mifuneyama Rakuen (Takeo, Saga Prefecture, Japan) is a 500,000 square meters park, home to flowers and trees of all seasons, such as cherry blossoms and azaleas. It is towered over by Mt. Mifune, which resembles a Chinese ship and is said to be the place where the legendary Empress Jingu moored her ship on her way home from the ancient kingdom of Silla.
This year, the venue hosts 14 exhibits: 13 artworks produced by teamLab with the use of projection mapping and other technologies, including light and sound. The 14th exhibit is a joint production with WASO, the new brand SHISEIDO skincare line, to convey WASO’s concept of “All things beautiful come from nature”.
360 Degrees Video “A Forest Where Gods Live Art Exhibition”
Aim of Collaboration
The name “Shiseido” comes from a passage in the Yi Jing, the Chinese classic literature, which reads, “Praise the virtues of the Earth, which nurtures new life and brings forth significant values.” Based on the corporate mission to “inspire a life of beauty and culture”, Shiseido has built a unique sense of beauty throughout its 145 years of history.
The spirit of new value creation, reflected in Shiseido’s company name underlines its art and culture support activities. In 1919, the first Shiseido president, Shinzo Fukuhara founded the Shiseido Gallery (Ginza, Tokyo) in order to support young up-and-coming artists, and in 1978, Shiseido Art House (Kakegawa, Shizuoka) was opened. Both spaces host exhibitions of various artworks and disseminate information on art and culture, offering beauty that anticipates the change of times.
The present collaboration fuses Shiseido’s tradition of placing value on beauty, and teamLab’s revolutionary and buzz-generating digital art, taken to a new level by technology. Through this project, the companies aim to offer new value that will surprise and excite audiences worldwide.

Event Outline
Title:         “teamLab: A Forest Where Gods Live Art Exhibition presented by Shiseido”
Venue:         Mifuneyama Rakuen (Takeo, Saga Prefecture, Japan)
Term:         July 14th - October 9th, 2017
Hours:         July 14th - August 14th 20:00 - 22:30 (last admission: 22:00)
          August 15th - October 9th 19:30 - 22:30 (last admission: 22:00)
Admission fee:         Adults: 1600 yen; high school & junior high school students: 1200 yen; elementary school students: 800 yen; babies and children under school age: free

Collaborative Exhibit
Title: WASO Tea House – “Flowers Bloom in an Infinite Universe, inside a Teacup”
The exhibit occupies a special tea house located in the park. The visitors can enjoy an original tea based on five ingredients (carrot, loquat leaf, tofu, white jelly mushroom, and honey) that are featured in the new skincare line WASO by brand SHISEIDO. The experience fuses the concept of WASO, “All things beautiful come from nature”, with that of the exhibition, “Nature Becomes Art”. Through the act of drinking tea, one can appreciate the original taste of the ingredients, but at the WASO tea house, the experience becomes art, allowing the visitors to explore the world of WASO through the five senses.
WASO Tea House Video
WASO
WASO is a new skincare line by brand SHISEIDO, which operates in 88 countries and regions worldwide. The new products will be released in July 2017, targeting Millennials in the USA and some Asian countries with the concept of “Feel beautiful in your own skin with skincare that makes the most of the ingredients”. WASO is based on the philosophy of Washoku, the tradition of Japanese food, which respects the uniqueness and natural flavor of each ingredient. WASO restores the ideal moisture balance in the skin and focuses on skincare concerns like dryness, oiliness, and visible pores. The line is step-free, so the products can be combined to one’s taste in order to bring out their unique natural beauty.
WASO Global Launch Film
Mifuneyama Rakuen
Mt. Mifune, literally “her majesty’s ship”, derives its name from the legend that Empress Jingu moored her ship here on her return from the ancient kingdom of Silla. It is 210 meters high and is the symbol of Takeo City, Saga Prefecture, Japan. Mt. Mifune appeared in school hymns since ancient times, and is a fond memory for many who were born or raised in Takeo. The magnificent mountain, towering serenely over the city, has a personality of its own. Against the backdrop of this Mt. Mifune lies Mifuneyama Rakuen, its abundant natural colors changing with every season. The Park was designated as a National Place of Scenic Beauty, the first of the kind in Saga Prefecture, in 2010.

teamLab
Company name:         teamLab Inc.
Representative Director:         Toshiyuki Inoko
Address:         Tosetsu Hongo Bldg. 5F, 1-11-6 Hongo, Bunkyo-ku, Tokyo, Japan
Established:         March 2001
Business activities:         A collective, interdisciplinary creative group that brings together professionals from various fields of practice in the digital society: programmers, engineers, CG animators, artists, mathematicians, architects, web and print graphic designers and editors. Referring to themselves as "ultratechnologists," the group aims to go beyond the boundaries between art, science, technology and creativity, through co-creative activities.
HP:        
http://teamlab.art/jp/
Exhibition details:        
https://www.teamlab.art/e/mifuneyama2017/
YouTube:
    
https://youtu.be/GdnDAP89LQY

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51597718&lang=en
Contacts
Shiseido Company, Limited
Tatsuyoshi Endo, +81-70-3852-2708
Corporate Communications Division
tatsuyoshi.endo@to.shiseido.co.jp

Permalink : http://me-newswire.net/news/4321/en

Nominum-led Panel Discussion at BlackHat Focuses on the Agility and Coverage Depth of DNS in Discovering and Blocking New Malware

Nominum Data Science Experts Join Academic and Telecom Industry Experts to Explain the Unique Insights DNS Data Enables to Protect Networks and Internet Users from Emerging Threats



REDWOOD CITY, Calif. -Wednesday, July 26th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Nominum™, the DNS-based security and services innovation leader, announced today it is leading a panel discussion at BlackHat USA titled “DNS: An Agile Defense Against Diverse, Damaging Attacks.” The panel of speakers features security researcher Nick Feamster, Professor and Deputy Director of the Princeton University Center for Information Technology Policy (CITP), and Matthew Carothers, Principal Security Architect with a leading North American ISP, along with Nominum security experts Yuriy Yuzifovich, Head of Security Research and Data Science, and Pierre Ehsani, Senior Director of Product Management.

The discussion will shed light on the depth and breadth of cyberthreats that can be detected and analyzed using DNS data – all in a matter of minutes – when it is combined with machine learning and proprietary algorithms. While DNS performs an essential network service, connecting users with applications and services they seek, security related enhancements turn DNS into an agile defense that can protect consumers and businesses against a wide range of web threats.

The Nominum-led panel session takes place at 2:30pm PDT on Thursday, July 27, 2017 in Oceanside F, Level 2 at the Mandalay Bay Hotel in Las Vegas. More information can be found at https://www.blackhat.com/us-17/business-hall/schedule/#dns-an-agile-defense-against-diverse-damaging-attacks-8213.

“The vast majority of cyberattacks rely on DNS to be successful. By examining DNS traffic, it is possible to pinpoint the unique queries these threats use to carry out their exploits,” said Yuriy Yuzifovich, Head of Security Research and Data Science for Nominum. “In fact, DNS data often detects malware faster, and finds more malware than alternative approaches like intensive forensic analysis of hosts. For devices like POS terminals and IoT gadgets that have little to no built-in security and are difficult to scan for malware, a DNS-based approach is highly effective.”

Nominum Data Science uses anonymized service provider, commercial and public data sources, along with advanced predictive intelligence techniques to analyze over 100 billion queries daily. The team combines its unique visibility into worldwide real-time DNS data and a patent-pending, unsupervised machine learning algorithm based on a neural network, to pick up correlation signals between domain names. This technology helps discover obscure domains that cybercriminals use to hide behind multiple machine-generated domains, including Domain Generated Algorithms (DGAs).

About Nominum

Nominum™ is a pioneer and global leader in DNS-based security and services innovation. The Silicon Valley company provides an integrated suite of carrier-grade DNS-based solutions that enable fixed and mobile operators to protect and enhance their networks, strengthen security for business and residential subscribers and offer innovative value-added services that can be monetized. The result is improved service agility, higher ARPU, increased brand loyalty and a strong competitive advantage. More than 130 service providers in over 40 countries trust Nominum to deliver a safe, customizable internet and promote greater value to over half a billion users. Nominum DNS software resolves 1.7 trillion queries around the globe every day—roughly 100 times more transactions than the combined daily volume of tweets, likes, and searches taking place on major web properties. For more information visit nominum.com.

Follow us on Twitter: @nominum https://twitter.com/nominum
Follow us on LinkedIn: https://www.linkedin.com/company/nominum
See us on YouTube: https://www.youtube.com/nominum
Read our latest blogs: http://nominum.com/blog/ | http://nominum.com/tech-blog/

Contacts

Nominum
Nancy MacGregor, +1-415-309-5185
PR Director
nancy.macgregor@nominum.com

UNITE with Tomorrowland descends on Dubai in the most spectacular way on 29th July 2017

 ~ The ultimate party travels across the world and debuts in Dubai at Festival City Arena ~

~ Concert bracelets must be collected in advance from Dubai Festival City Mall ~



Dubai, United Arab Emirates, -Thursday, July 27th 2017 [ ME NewsWire ]

Over 200,000 people witnessed the magic unravel at the first weekend of Tomorrowland in Belgium. With epic performances, massive fireworks, acrobats and ornate decorations, the festival left audiences enthralled at the legendary Holy Grounds. This weekend the magical journey continues in the event called UNITE with Tomorrowland Dubai at Festival City Arena on 29th July 2017.

To be a part of the first-ever UNITE with Tomorrowland Dubai, festival-goers must exchange their tickets with personalized concert bracelets prior to the event. These RFID bracelets ensure entry to the event and can be obtained from the Bracelet Collection Booth at Dubai Festival City Mall every day between 10:00am and 09:00pm.

UNITE with Tomorrowland Dubai begins at 2pm with Arcade 82, followed by incredible sets featuring Barry Fore, Siege, Robert Falcon, Ferreck Dawn, Franky Rizardo, Tom Swoon, Mikael Weermeets and Martin Solveig LIVE on the Dubai stage. The extravaganza promises to create a truly magical experience with a live satellite connection which will connect KSHMR, Armin van Buuren and Dimitri Vegas & Like Mike to the crowds in Dubai and simultaneously to 7 other countries around the world! LED screen shows will not only mirror the Holy Grounds in Belgium, but also showcase the special effects which will be synced in all countries, making everyone feel as if they are on the Tomorrowland dance floor.

“We’re very excited to join more than 200,000 People of Tomorrow via satellite from the legendary Mainstage of Tomorrowland in Belgium to the party in Dubai. The evening will be full of magic, madness and surprises as spectacular artists create waves from the turn tables at UNITE with Tomorrowland Dubai. Exchange your tickets for festival bracelets and get ready for an unforgettable journey.” says Nicolas Vandenabeele, Director, Envie Events.

The 13th edition of Tomorrowland took festival-goers by storm, with some of the greatest artists coming together at the first weekend in Boom, Belgium. Temperatures reached record-breaking levels with incredible performances featuring some of the biggest names in dance music across the world such as Axwell^Ingrosso, Paul van Dyk, Tiesto, Steve Aoki, Martin Solveig, Armin van Burren, Martin Garrix, Dimitri Vegas & Like Mike, Afrojack, Marshmello and so many more! Keeping up with the festival’s evolution, the main stage this year has a spectacular set-up in line with the ‘Amicorum Spectaculum’ theme, that is fully equipped with acrobats, meticulously moving parts, and some of the biggest talent the scene has to offer.

Live Today, Love Tomorrow, Unite Forever.

Full Artist Line Up- UNITE with Tomorrowland Dubai: https://www.youtube.com/watch?v=tKyXxyyopgc&feature=youtu.be

Tomorrowland 2017 Trailer: https://tomorrowland.app.box.com/s/jlrua7n1ffageda6x4bwi4ky1346ikto

Tomorrowland 2017 Images:

https://tomorrowland.app.box.com/s/yeg8ywyz3z0tgsbr4v1ehdtdzpv2j2w3/folder/31408903746

Note to the Editor:

Date: Saturday, 29th July, 2017

Time: 02:00pm to 03:00am

Venue: Dubai Festival City Indoor Arena

Age Limit: Strictly 21+

Tickets are on sale now via Platinum List- https://dubai.platinumlist.net/event-tickets/48105/unite-with-tomorrowland?show=51088&_ga=2.247327681.418474548.1500203029-1425192715.1478436217

Tickets are also available on the Dubai Calendar App or at Festival City Mall

IOs App store: https://itunes.apple.com/us/app/dubai-calendar/id501018460?mt=8

For table bookings contact: +971 4 4573212 or vip@envie.ae

Dropbox link to high resolution photographs of UNITE with Tomorrowland – https://www.dropbox.com/sh/mlm5zso2bljn9i2/AAAK_XGa_clB1UtsgVhCLNvTa?dl=0

About Envie Events

Envie Events is proud producer, organizer and promoter of some of the most spectacular, immersive and innovative Dance Music Events in the Middle East including Sensation Dubai, Martin Garrix on NYE 2015, I am Hardwell 2016, Armin Only Embrace 2016.

With over 25 years of combined experience in the entertainment, hospitality, and nightlife industry, the company’s events captivate tour senses and inspire a unique level of fan interaction enhanced by state-of-the-art lighting, pyrotechnics and sound design, large-scale art installations and theatrical performers. Having hosted the first world exclusive open-air edition of Sensation in Dubai, two Mega Night Club operations in Europe and various annual partnerships with globally-renowned concepts such as Sensation, Tomorrowland, WMC Miami, and Summer Clubbing Ibiza, Envie Events aspires to become the ultimate destination of choice for events and concerts in Dubai – attracting the entire MENA Region and beyond.

Contacts

Malaika Fernandes

00971 52 954 9333

malaika.fernandes@mediaagency-me.com



Bipin Pathak

Bipin.pathak@mediaagency-me.com


Permalink : http://www.me-newswire.net/news/4317/en 

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®

INGELHEIM, Germany -Thursday, July 27th 2017 [ ME NewsWire ]

    First patient enrolled into VOLTAIRE-X; an interchangeability study designed to assess whether BI 695501 is interchangeable with Humira®1
    First study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate
    BI 695501 is currently under review by regulatory authorities2

(BUSINESS WIRE)-- Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate.

The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1

“We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim. “The initiation of this study reinforces our commitment to improving the lives of patients suffering from serious chronic or life-threatening diseases through biosimilars. With biosimilars, we will have the opportunity to expand treatment options while at the same time providing value to the healthcare system.”

The VOLTAIRE-X study (NCT03210259)1, is being conducted in 240 patients with moderate-to-severe chronic plaque psoriasis. Results from the study are expected in the second half of 2019.1

BI 695501 has been accepted for regulatory review by the European Medicines Agency and the U.S. Food and Drug Administration.2 Phase III results demonstrating clinical equivalence of BI 695501 to Humira® in people living with rheumatoid arthritis were recently presented at the annual European Congress of Rheumatology.3

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/interchangeability-study-bi-695501-vs-humira

Contacts

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Julia Knebel
Phone: +49 6132 – 77 95614
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
www.boehringer-ingelheim.com

People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey

INGELHEIM, Germany -Monday, July 24th 2017 [ ME NewsWire ]
• 61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1
• Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1
• Healthcare teams emphasise the need of a strong support network and multi-disciplinary care for people with IPF
(BUSINESS WIRE)-- New results from a global survey supported by Boehringer Ingelheim1 reveal the emotional and practical challenges facing people with idiopathic pulmonary fibrosis (IPF). Patients are impacted by feelings of anxiety, fear, uncertainty and hopelessness, as well as a restriction in everyday activities.1 However, a range of both medical and non-medical support is available to help them cope with their disease.2
The survey uncovers patient concerns about the irreversible progression of their disease. Patients are especially worried over acute IPF exacerbations - a rapid deterioration of symptoms within days or weeks, which can significantly reduce chances of survival and lead to death within a few months.3 More than 150 patients across nine countries were interviewed. 61% of respondents report that they are worried (39%) or extremely worried (22%) about experiencing an acute IPF exacerbation.1
Patients also highlighted the impact of the physical limitations caused by the disease, the importance of knowing how long they will be able to be active and continue with their hobbies and accepting and learning how to live with the condition.1
Dr. Marlies Wijsenbeek, pulmonologist, Erasmus MC, The Netherlands commented, “We know a lot about the physiological changes that occur in IPF but surveys like this help us to better understand the psychological burden. While medical care is available to help slow the progression of IPF right after diagnosis, it is also crucial that patients are given emotional support from the earliest stage possible to help minimise anxiety associated with the disease. In daily practice we need to continuously remind ourselves that we are not just treating lungs, we are treating people.”
Support for patients dealing with the challenge of IPF goes beyond drug therapy and can include supply of additional oxygen when needed and pulmonary rehabilitation programmes, including advice on the diet and exercise plan most appropriate to an individual patient’s disease and medication.2 Patients can benefit from speaking with their physician about the challenges they face, however further emotional and practical support can also be gained from the wider team of healthcare professionals, such as nursing support, social workers, psychologists and physiotherapists, as well as family, friends and patient support groups.
Marianne Seiter, nurse specialised in interstitial lung diseases, Thoraxklinik, Universitätsklinikum Heidelberg, Germany, said, “A strong support network is vital for patients with IPF to help address the full impact of the disease. Nurses, and other members of the multi-disciplinary team, can help patients take a pro-active approach to managing their condition through a range of care options. With appropriate support we can work together to help patients maintain the best quality of life possible.”
Stephen Jones, an IPF patient from UK said, “As IPF patients, we know our lungs will deteriorate and it will be hard to breathe, but we don’t know when that is going to happen. This can create a lot of worry and anxiety. It is important that we make the very best of the wide range of available support from healthcare professionals and patient groups, as well as close family and friends.”
Improving the wellbeing of people with fibrosing lung diseases such as IPF is a priority for Boehringer Ingelheim. As part of this commitment, Boehringer Ingelheim is currently enrolling patients to participate in further clinical trials investigating the efficacy of nintedanib in treating interstitial lung disease associated with conditions other than IPF, including people with systemic sclerosis who have also developed interstitial lung disease (SSc-ILD) and people with other progressive fibrosing interstitial lung diseases (PF-ILD).*
*Nintedanib is currently not approved for use in SSc ILD or PF ILD and its safety and efficacy has not yet been fully established.

Please click on the link below for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/ipf_survey_burden_of_disease
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com

Permalink : http://me-newswire.net/news/4294/en

Toshiba's Visconti™4 Image Recognition Processor Powers DENSO's Front-Camera-Based Active Safety System

TOKYO -Thursday, July 27th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Toshiba Electronic Devices & Storage Corporation today announced that DENSO Corporation (DENSO) is deploying Visconti™4, its latest image-recognition processor dedicated to automotive applications, in next generation, front-camera-based active safety systems. Visconti™4 is a leading-edge, multi-engine road-safety solution that provides drivers with real-time analytics of road conditions and potential dangers.

Electronic systems are taking on an increasingly central role in driving, including advanced driver assistance systems and support for autonomous vehicles, and particularly in promoting road safety. The latest iteration of the influential European New Car Assessment Programme (Euro NCAP), the EU-backed safety standard, adds criteria for evaluating anti-collision features that improve protection for bicyclists and pedestrians.

The Visconti™4 image recognition processor is equipped with eight media processing engines, allowing it to execute eight applications simultaneously. It can detect and analyze camera-generated images and recognizes traffic lanes; nearby vehicles, both parked and moving; traffic signs and signals; the headlights of oncoming vehicles; plus the most vulnerable road users of all, bicyclists and pedestrians.

Visconti™4 has double the number of processing engines of its predecessor, the Visconti™2, used by DENSO since 2015. It also integrates a new image recognition algorithm, Enhanced CoHOG Accelerator1 that delivers enhanced processing of luminance differences between objects and their backgrounds to better detect pedestrians at night and low light conditions.

Toshiba and DENSO are also cooperating in AI, on the development of deep neural network-intellectual property (DNN-IP) for use in image recognition, and plan to bring this state-of-the-art technology to future additions to the Visconti series.

The global market of vehicle-mounted cameras is expected to approach $9.6 billion in 20212. Toshiba is committed respond to with automotive semiconductor solutions that further pursue traffic safety.

Notes
1. CoHOG is Toshiba’s original Co-occurrence Histograms of Oriented Gradients technology
2. Techno Systems Research Co., Ltd. “Automotive Camera Market Analysis, 2016”

*Visconti is a trademark of Toshiba Corporation

About Toshiba Electronic Devices & Storage Corporation

Toshiba Electronic Devices & Storage Corporation (TDSC) combines the vigor of a new company with the wisdom of experience. Since being spun off from Toshiba Corporation in July 2017, we have taken our place among the leading general devices companies, and offer our customers and business partners outstanding solutions in discrete semiconductors, system LSIs and HDD.

Our 19,000 employees around the world share a determination to maximize the value of our products, and emphasize close collaboration with customers to promote co-creation of value and new markets. We look forward to building on annual sales now surpassing 700-billion yen (US$6 billion) and to contributing to a better future for people everywhere.
Find out more about us at https://toshiba.semicon-storage.com/ap-en/company.html

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51596606&lang=en

Contacts

Media Inquiries:
Toshiba Electronic Devices & Storage Corporation
Chiaki Nagasawa, +81-3-3457-4963
Digital Marketing Department
semicon-NR-mailbox@ml.toshiba.co.jp

Permalink : http://www.me-newswire.net/news/4316/en

Mitsui Chemicals Starts Accepting Applications on September 1st for 2018 Mitsui Chemicals Catalysis Science Award

TOKYO-Wednesday, July 26th 2017 [ ME NewsWire ]
(BUSINESS WIRE)-- Mitsui Chemicals Inc. (Location: Minato-ku, Tokyo; President & CEO: Tsutomu Tannowa) (TOKYO:4183) announced that Mitsui Chemicals Catalysis Science Award will begin accepting applications for the “2018 Mitsui Chemicals Catalysis Science Award” on September 1st via web site of the company.
Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Award in 2004 with the aim of contributing to the sustainable development of chemistry and the chemical industry. This award is designed to recognize researchers who have made outstanding achievements in catalysis science.
Web Entry for the Award http://www.mitsuichem.com/techno/csa/index.htm

1.  Awards
         
Mitsui Chemicals Catalysis Science Award
(Up to one researcher)
    
Mitsui Chemicals Catalysis Science Award of Encouragement
(Up to two researchers)
Eligible applicant
(by the date of Apr. 1st 2017)
     The researcher who made the best achievements in the catalysis science field.         The researcher who made the most original achievements in the catalysis science field.
     47 years or younger         37 years or younger
Prize        
A commemorative plaque
and a cash prize of 5 million yen
     A commemorative plaque
and a cash prize of 1 million yen

2.  Selection schedule
The winners will be selected by a selection committee organized by Mitsui Chemicals, Inc., to consist of several world-class academic experts in catalysis science and a representative of Mitsui Chemicals.
Web entry start         September 1st, 2017
Deadline         December 31st, 2017
Announcement of winners         Around June 2018 on the website, specialized magazines, etc.
Award ceremony and Commemorative lectures
     The winners will be requested to deliver commemorative lectures in Autumn 2018. The travel expenses including accommodation charges will be paid. The details will be announced later.

Application forms, submission information and details will be indicated as above URL.
Contacts
Mitsui Chemicals, Inc.
Takashi Kawamoto, +81-3-6253-2100
Corporate Communications Division

Permalink : http://me-newswire.net/news/4311/en

Morpho Licence2Go: the Digital Licence Platform from OT-Morpho

SYDNEY-Wednesday, July 26th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- OT-Morpho, a world leader in digital security and identification technologies, has launched through its Australian subsidiary Morpho Australasia, an innovative solution for digital licences, aptly named Licence2Go. The platform allows the holders to dematerialize identification documents in their smartphone, benefiting from security and flexibility, with availability ‘Anywhere, anytime, on the go.’

The main licence app is complemented by a verification app, whereby police or others requiring ID checks can verify the details of the licence holder without needing to hold the device. Licence2Go works on the principle of Privacy by Design, and at all stages, control of personal data remains with the device owner. Contactless verification takes place between devices, with no personal data transmitted, even in areas away from mobile coverage. Depending on the level of authority required for a specific transaction, the licence holder is able to choose which information is shared (Name, address, DOB*, etc.). Licence details can be visually verified in-person or online, where facial verification can be used in the case of secure transactions such as loan applications.

Morpho Australasia is working with Transport authorities among others to customize the solution and brand the apps with the design of the issuing authority. The company has already begun a pilot study with an Australian Transport authority and is working to produce further pilots around the Asia-Pacific region in the second half of 2017.

Tim Ferris, OT-Morpho, managing director for Morpho Australasia, said of the trial: “Licence2Go is able to connect identity from the physical world into the digital world. We have had some great feedback from several jurisdictions and look forward to when leaving the physical document at home is no longer a problem.”

The most obvious application for the platform is with digital driving licences, but the concept is readily adapted elsewhere within government services and in the private sector, including membership cards, loyalty cards and corporate identification cards.

*Date Of Birth

OT-Morpho is a world leader in digital security & identification technologies with the ambition to empower citizens and consumers alike to interact, pay, connect, commute, travel and even vote in ways that are now possible in a connected world.

As our physical and digital, civil and commercial lifestyles converge, OT-Morpho stands precisely at that crossroads to leverage the best in security and identity technologies and offer customized solutions to a wide range of international clients from key industries, including Financial services, Telecom, Identity, Security and IoT.

With close to €3bn in revenues and more than 14,000 employees, OT-Morpho is the result of the merger between OT (Oberthur Technologies) and Safran Identity & Security (Morpho) completed on 31 May 2017. Temporarily designated by the name "OT-Morpho", the new company will unveil its new name in September of this year.

For more information:
www.morpho.com and www.oberthur.com
Follow @Safran_Morpho and @OT_TheMcompany on Twitter.

Contacts

OT-Morpho
Press contacts
Isabelle de BUYER, T + 33 (0)1 30 20 22 67
isabelle.de-buyer@morpho.com
or
Julien TAHMISSIAN, T + 33 (0)1 58 47 90 54
julien.tahmissian@havas.com

Permalink : http://www.me-newswire.net/news/4307/en